The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 2 October 2000.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 365K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freeman, G. J.
Right arrow Articles by Honjo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freeman, G. J.
Right arrow Articles by Honjo, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/10/1027/ $5.00
The Journal of Experimental Medicine, Volume 192, Number 7, October 2, 2000 1027-1034


Original Article

Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Gordon J. Freemana, Andrew J. Longb, Yoshiko Iwaic, Karen Bourqueb, Tatyana Chernovaa, Hiroyuki Nishimurac, Lori J. Fitzb, Nelly Malenkovicha, Taku Okazakic, Michael C. Byrneb, Heidi F. Hortonb, Lynette Fouserb, Laura Carterb, Vincent Lingb, Michael R. Bowmanb, Beatriz M. Carrenob, Mary Collinsb, Clive R. Woodb, and Tasuku Honjoc
a Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
b Genetics Institute, Wyeth-Ayerst Research, Cambridge, Massachusetts 02140
c Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan

Correspondence to: Tasuku Honjo, Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan. Tel:81-75-753-4371 Fax:81-75-753-4388

PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells. Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features. We report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family. Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. In addition, PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation. PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon {gamma}, and activated human and murine dendritic cells. In addition, PD-L1 is expressed in nonlymphoid tissues such as heart and lung. The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may determine the extent of T cell activation and consequently the threshold between tolerance and autoimmunity. PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently determine the extent of immune responses at sites of inflammation.

Key Words: binding, proliferation inhibition, cytokine secretion inhibition, tissue expression, peripheral tolerance


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS